1 Weilin Q, Weihu F, Wenhang Q.The pharmacology and clinical uses of naftopidil[J].Chinese J New Drugs, 2001;10:579-82 2 Sponer G, Borbe HO, Muller-Bockmann B, Freud P, Jakob B. Naftopodil, a new adrenoceptor blocking agent With Ca(2+)-antagonistic properties;interaction with adrenoceptors[J].J Cardiovasc Pharmacol, 1992;20:1006-13 3 Borbe HO, Metzenauer P, Szelcnyi I.5-HT1A-agonistic properties of naftopidil, a novel antihypertensive drug [J].Eur J Pharmacol, 1991;205:105-7 4 Alarayyed NA, Prichard BN, Betteridge DJ, Smith CC.Differential action of naftopidil, doxazoxin and nifedipine on platelet thromboxane generation and platelet-derived growth factor efflux in vitro[J].Platelets, 2002;13:267-71 5 Alarayyed NA, CooperMB, Prichard BN, Betteridge DJ, Smith CC.In vitro adrenaline and collagen-induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine[J].Br J Clin Pharmacol, 1997;43:415-20 6 Tsukiyama H, Otsuke K, Ono S.Hemodynamic effects of a new α-adrenoceptor blocking agent, naftopidil in patients with essential hypertension[J].J Clin Med, 1992;8:S89-96 7 Pellegrino J, Pellegrino AS, Cushman AK.A Sterotaxic atlas of the Brian[M].Plenum Press:New York, 1979 8 徐淑云, 王洪.降压药机理实验[A].见:徐淑云, 卞如濂, 陈修, 主编.药理实验方法学[M].第2 版.北京:人民卫生出版社, 1991:827 9 李宁忱, 张晓春, 王晓峰, 吴宏飞, 那彦群, 郭应禄.新型α1 受体阻滞剂萘哌地尔是治疗良性前列腺增生的临床研究[J].中华泌尿外科杂志, 2004;25:637-40 10 王会玖, 黄燮南, 蒋青松, 吴芹, 孙安盛, 石京山.萘哌地尔衍生物BWYJ 扩血管效应及其机制研究[J].中国临床药理学与治疗学, 2004;9:1393-7 |